• Patients must be able to understand the nature of the trial and provide a signed and dated informed consent form prior to screening.

• Aged at least 18 years old when sign ICF.

• Histological or cytological confirmed locally advanced or metastatic NSCLC.

• Patients must exhibit Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1 at ICF signature with no deterioration over the previous 2 weeks.

• Predicted life expectancy ≥ 12 weeks.

• Patients with brain metastasis (BM) can only be enrolled under the condition that BM is previously treated and stable e.g. no evidence of progression for at least 2 weeks after CNS-directed treatment as ascertained by clinical examination and brain imaging (magnetic resonance image \[MRI\] or computed tomography \[CT\] scan) during the screening period), neurologically asymptomatic and not require corticosteroid treatment.

• Adequate organ system functions, as outlined below

‣ Absolute neutrophil count (ANC) ≥ 1.5 x 109/L

⁃ Absolute lymphocyte count ≥ 0.8 x 109/L

⁃ Platelets ≥ 100 x 109/L

⁃ Hemoglobin ≥ 9 g/dL

⁃ Total bilirubin ≤ 1.5 x ULN if no liver metastases or ≤ 3 x ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases

⁃ Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN if no liver involvement or ≤ 5 x ULN with liver involvement

⁃ Creatinine ≤ 1.5 x ULN, or measured creatinine clearance ≥ 50 mL/min as calculated by the Cockcroft-Gault method

⁃ International normalized ratio (INR) ≤ 1.5 x ULN and activated partial thromboplastin time (APTT) ≤ 1.5 x ULN;

⁃ Serum amylase ≤ 1.5 x ULN and serum lipase ≤ 1.5 x ULN

• Male subjects with a female partner who intend to have children should use barrier contraception (e.g. condom) during their participation in the clinical study until 6 months after the last dose. Male subjects should not donate sperm during the clinical study until 6 months after the last dose. If the male subject has fertility requirements, it is recommended that sperm be frozen prior to the start of the clinical study.

• Female subjects should use contraception at screening until 6 weeks after the last dose of DZD9008 or 3 months after the last dose of AZD4205, whichever is later, should not be breastfeeding and should have a negative pregnancy test (blood or urine β-HCG) at the time of screening.

∙ Part A specific inclusion criteria:

• Subjects should harbour any type of EGFR mutation.

• Subjects should have progressed on, or be intolerant of prior standard systemic therapy for metastatic/locally advanced disease.

∙ Part B specific inclusion criteria:

• Subjects must have documented EGFR sensitizing mutation from a local certified laboratory.

• Subjects should have progressed on, or be intolerant of prior standard systemic therapy for metastatic/locally advanced disease.

• Patient must have measurable disease according to RECIST 1.1: At least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes which must have short axis ≥15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and which is suitable for repeated measurement.

• Agree and be willing to provide an adequate amount of the required tumor tissue for exploratory studies.